Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Post-Mkt 09-04 16:25:23 EDT

2.48

+0.06

+2.48%

盘后2.48

+0.000.00%

16:10 EDT

High2.49	Low2.38	Vol609.93K
Open2.38	D1 Closing2.42	Amplitude4.55%
Mkt Cap297.60M	Tradable Cap260.24M	Total Shares120.00M
T/O1.50M	T/O Rate0.58%	Tradable Shares104.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":2.48,"timestamp":1788552000000,"preClose":2.42,"halted":0,"volume":609928,"hourTrading":{"tag":"盘后","latestPrice":2.48,"preClose":2.48,"latestTime":"16:10 EDT","volume":1583,"amount":3925.7999501,"timestamp":1788552604773,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.024793388429752088,"floatShares":104935918,"shares":120000000,"eps":-1.052849,"marketStatus":"Post-Mkt","change":0.06,"latestTime":"09-04 16:25:23 EDT","open":2.38,"high":2.49,"low":2.38,"amount":1502326,"amplitude":0.045455,"askPrice":2.71,"askSize":100,"bidPrice":2.46,"bidSize":56,"shortable":3,"etf":0,"ttmEps":-1.052849,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788566400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":2.42,"preHourTrading":{"tag":"盘前","latestPrice":2.44,"preClose":2.42,"latestTime":"09:18 EDT","volume":1498,"amount":3655.746913,"timestamp":1788527922990,"change":0.02,"changeRate":0.008264,"amplitude":0.08814},"postHourTrading":{"tag":"盘后","latestPrice":2.48,"preClose":2.48,"latestTime":"16:10 EDT","volume":1583,"amount":3925.7999501,"timestamp":1788552604773,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.719276,"impliedVol":1.0285,"impliedVolPercentile":0.4206},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2664876078","title":"Fate Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat on FT819 Autoimmune CAR-T Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2664876078","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664876078?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:03","pubTimestamp":1788433419,"startTime":"0","endTime":"0","summary":"Fate Therapeutics joins Cantor Global Healthcare Conference fireside chat on FT819 autoimmune CAR-T programFate Therapeutics management will join a fireside chat at the 2026 Annual Cantor Global Healt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL7WdDvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","BCDF","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","SG9999014039.USD","IE00BGHQF748.EUR","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664584356","title":"Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664584356","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664584356?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:31","pubTimestamp":1788366686,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc ($FATE) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is advancing a new early stage trial call...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-expands-into-autoimmune-disease-with-new-ft839-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-expands-into-autoimmune-disease-with-new-ft839-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659177808","title":"Fate Therapeutics intiates first patient in RECLAIM-LN trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659177808","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659177808?lang=en_us&edition=fundamental","pubTime":"2026-08-16 21:40","pubTimestamp":1786887614,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE) highlighted the initiation of and treatment of the first patient in RECLAIM-LN, its Phase 2 potentially registrational cli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-intiates-first-patient-in-reclaim-ln-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-intiates-first-patient-in-reclaim-ln-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144490","title":"Fate Therapeutics Price Target Maintained with a $7.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144490?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:20","pubTimestamp":1786713600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659314328","title":"Fate Therapeutics - Patients to Receive Single 900 Mln-Cell Dose of Ft819; Primary Endpoint at Week 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2659314328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659314328?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA8L2JHJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659143408","title":"Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659143408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659143408?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA8L2JHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659450421","title":"Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659450421","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659450421?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345223/24675/en/fate-therapeutics-initiates-potentially-registrational-reclaim-ln-clinical-trial-of-ft819-for-the-treatment-of-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4077","LABU","FATE","IDNA","NVIB","CAR","MEDX","BK4230","GDOC","HYLG","SLE","BK4139","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659673481","title":"Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2659673481","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659673481?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:20","pubTimestamp":1786652418,"startTime":"0","endTime":"0","summary":"Equillium Q2 post narrower net loss than expected; starts R&D initiativesOverviewUS biotech innovator's Q2 net loss narrowed and beat analyst expectationsQ2 loss per share beat analyst expectationsCom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4568","ARTL","EQ","FATE","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659169563","title":"Analysts Conflicted on These Healthcare Names: Fate Therapeutics (FATE) and Mediwound (MDWD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659169563","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659169563?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:50","pubTimestamp":1786639807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE) and Mediwound (MDWD). Fat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-fate-therapeutics-fate-and-mediwound-mdwd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-fate-therapeutics-fate-and-mediwound-mdwd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XBI","XLV","BK4139","LU0128526141.USD","BK4588","HCSG","BK4585","BK4137","MDWD","BK4581","FATE","LU0029874061.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659163408","title":"Fate Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659163408","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659163408?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:54","pubTimestamp":1786632885,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryFate Therapeutics IncFATE.OQreported a quarterly adjusted loss of 25 cents per share for the quarter ended June 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A1NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659527901","title":"Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659527901","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659527901?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:55","pubTimestamp":1786625739,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.29) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61173030/fate-therapeutics-q2-eps-0-25-beats-0-27-estimate-sales-2-082m-beat-1-366m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659523471","title":"Fate Therapeutics - Expects Operating Runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2659523471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659523471?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA3Y20RN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659547741","title":"Fate Therapeutics Q2 Operating Expenses USD 33.216 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659547741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659547741?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX4MD16F:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658099472","title":"Fate Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658099472","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658099472?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:03","pubTimestamp":1786446188,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc <FATE.OQ> expected to post a loss of27cents a share - Earnings PreviewFate Therapeutics IncFATE.OQFATE.Ois expected to  show a fall in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N4480U8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645638","title":"Don't Ignore The Insider Selling In Fate Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645638","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645638?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:52","pubTimestamp":1786103576,"startTime":"0","endTime":"0","summary":"We'd be surprised if Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders haven't noticed that the President, Bahram...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/dont-ignore-the-insider-selling-in-fate-therapeutics","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/dont-ignore-the-insider-selling-in-fate-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610934","title":"Fate Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610934","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610934?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:08","pubTimestamp":1786100886,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc <FATE.OQ> expected to post a loss of27cents a share - Earnings PreviewFate Therapeutics IncFATE.OQFATE.Ois expected to  show a fall in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4440Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656118301","title":"Fate Therapeutics Grants New-Hire Inducement Equity Awards, Including 37,300 Options at $2.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2656118301","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656118301?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:10","pubTimestamp":1785787818,"startTime":"0","endTime":"0","summary":"Fate Therapeutics grants new-hire inducement equity awards, including 37,300 options at $2.45Fate Therapeutics disclosed August 1, 2026 inducement equity awards to newly hired non-executive employees.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL41mXYS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014039.USD","LU0314104364.USD","FATE","NDAQ","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4588","BCDF","LU2210149790.SGD","LU2210150020.SGD","SG9999014021.USD","BK4585","LU2095319765.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656078183","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656078183","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656078183?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Aug.  03, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337860/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650971931","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2650971931","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650971931?lang=en_us&edition=fundamental","pubTime":"2026-07-10 03:23","pubTimestamp":1783625029,"startTime":"0","endTime":"0","summary":"Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF  down 0.4%.The iShares Biotechnology ETF  increased 0.3%.In corporate news, Fate Therapeutics  shares rose nearly 6% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","XLV","LU0128526141.USD","HCSG","BK4588","LU0029874061.USD","BK4585","LABU","XBI","IBB","BK4137","BK4581","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650797509","title":"Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839","url":"https://stock-news.laohu8.com/highlight/detail?id=2650797509","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650797509?lang=en_us&edition=fundamental","pubTime":"2026-07-10 02:47","pubTimestamp":1783622867,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  shares were up more than 7% in Thursday trading after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate designed to treat autoimmune diseases.The company said that it now plans to advance FT839 into a trial designed to assess the product candidate across several autoimmune diseases, when given in combination with standard-of-care therapy and without conditioning chemotherapy.Fate said enrollment in the phase 1/2 trial is expected to start in H2.Price: 3.14, Change: +0.21, Percent Change: +7.17","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","FATE","BK4139","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0472},{"period":"1month","weight":-0.0584},{"period":"3month","weight":0.2222},{"period":"6month","weight":0.8195},{"period":"1year","weight":1.42},{"period":"ytd","weight":1.4629}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.079338},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.000833},{"month":7,"riseRate":0.384615,"avgChangeRate":0.039214},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.024594},{"month":9,"riseRate":0.461538,"avgChangeRate":0.00163},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}